Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Arcturus Therapeutics
ISIN US03969T1097
|WKN A2PMAS
Market cap (in EUR)
166 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 166 m |
| EPS, EUR | -2.23 |
| P/B ratio | 0.8 |
| P/E ratio | 9.9 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 128 m |
| Net income, EUR | -75 m |
| Profit margin | -58.49% |
What ETF is Arcturus Therapeutics in?
There is 1 ETF which contains Arcturus Therapeutics.
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.02% | Equity United States Health Care Biotech | 44 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.